Departing from industry norms, Curie.Bio intentionally allocates a large equity stake to founders. They see this not just as fair but as a utilitarian strategy to gain a competitive advantage in sourcing the rarest and most valuable scientific ideas, which ultimately drives fund returns.

To solve the critical challenge of hiring expensive, specialized talent, Curie.Bio offers its portfolio companies access to a 100+ person team of elite "drug makers" on a fractional, at-cost basis. This provides world-class expertise on demand without the burden of full-time payroll, de-risking early development.

Top VCs are reviving the early, hands-on model of pioneers like Arthur Rock. Instead of just investing, firms are co-designing new labs from scratch, providing compute, capital, and commercial guidance. This "company creation" approach is viable again as capital is no longer the primary bottleneck for ambitious, frontier-tech ideas.

Unlike venture creation firms that generate ideas internally, Curie.bio operates on a 'Freedom for Founders' principle. It believes the best ideas come from external innovators and its role is to augment them with capital-efficient support, fractional expertise, and operational help to translate those ideas into companies.

The biotech venture model is built on syndication, not competition. As a drug progresses, capital requirements balloon to hundreds of millions for late-stage trials, far exceeding any single VC's capacity. This structural reality forces firms to co-invest and partner throughout a company's lifecycle.

Beyond providing non-dilutive capital, the Flemish government's funding system (VLAIO) includes access to experts who actively challenge a startup's scientific proposals. This process forces strategic rigor and helps refine projects to be more translatable and robust. This built-in expert review is a key advantage of the Belgian biotech ecosystem, making companies smarter, not just richer.

Jeito's investment strategy focuses on taking significant equity stakes in companies with early clinical data. This allows them to secure a board seat and actively influence strategy. They differentiate themselves by providing portfolio companies with access to a deep network of in-house experts in regulatory affairs, commercialization, and business development, acting as a true operational partner beyond just capital.

Startups need elite talent to succeed but can't afford or attract it. Curie.bio solves this by providing its portfolio companies with on-demand, fractional access to a team of over 100 world-class drug hunters. This allows founders to tap into top-tier expertise without incurring high fixed costs.

Europe's strong science is often held back by a lack of serial entrepreneurs, difficulty in raising follow-on funding, and a localized competitive view. Curie.Bio’s model directly counters these issues by providing an experienced drug-making team, a clear funding path, and an embedded global market perspective.